Facebook Instagram X-twitter Linkedin Youtube Spotify Apple Search

Duchenne News Tags: Edgewise Therapeutics

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Roche Santhera Sarepta Therapeutics Satellos Bioscience Solid Biosciences Upsher-Smith Wave Life Sciences
September 7, 2022

Edgewise Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506

On Sept. 7, 2022, Edgewise announced that the FDA has authorized its Phase 2 clinical trial for the treatment of Duchenne. They expect to begin dosing participants in the fourth...
Read More
July 14, 2022

Edgewise Therapeutics Announces Initiation of CANYON Phase 2 Clinical Trial Evaluating EDG-5506

On July 12, 2022, Edgewise Therapeutics shared a press release announcing the opening of the CANYON Phase 2 clinical trial of their investigational compound, EDG-5506, in individuals with Becker muscular...
Read More
Edgewise Duchenne News
June 21, 2022

Edgewise Therapeutics Announces Positive Results from the ARCH Open Label Study of EDG-5506

On June 20, 2022, Edgewise Therapeutics announced positive results from the ARCH open label study of EDG-5506.
Read More